A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

NCT05791201 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes

Interventions

DRUG: VX-264

Sponsor

Vertex Pharmaceuticals Incorporated